BTIG Research upgraded shares of Pulse Biosciences (NASDAQ:PLSE – Free Report) to a strong-buy rating in a report published on Wednesday,Zacks reports.
A number of other brokerages have also recently weighed in on PLSE. Needham & Company LLC assumed coverage on shares of Pulse Biosciences in a research note on Monday, August 17th. They issued a “buy” rating and a $58.00 price objective for the company. Canaccord Genuity Group raised their target price on shares of Pulse Biosciences from $32.00 to $43.00 and gave the company a “buy” rating in a research note on Monday, August 10th. Freedom Capital upgraded shares of Pulse Biosciences to a “strong-buy” rating in a report on Wednesday, September 9th. Wall Street Zen raised shares of Pulse Biosciences from a “sell” rating to a “hold” rating in a research report on Sunday, September 6th. Finally, Mizuho set a $45.00 target price on shares of Pulse Biosciences in a research report on Monday, August 10th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $50.20.
Get Our Latest Analysis on PLSE
Pulse Biosciences Stock Performance
Pulse Biosciences (NASDAQ:PLSE – Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.07). The company had revenue of $0.43 million during the quarter, compared to analyst estimates of $0.53 million. Pulse Biosciences had a negative return on equity of 94.42% and a negative net margin of 6,755.78%. As a group, equities research analysts forecast that Pulse Biosciences will post -1.29 earnings per share for the current year.
Insider Activity
In related news, COO Liane Teplitsky bought 1,001 shares of the company’s stock in a transaction that occurred on Tuesday, September 1st. The shares were acquired at an average price of $49.95 per share, with a total value of $49,999.95. Following the completion of the transaction, the chief operating officer owned 4,095 shares of the company’s stock, valued at $204,545.25. The trade was a 32.35% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders have acquired a total of 4,095 shares of company stock valued at $199,931 in the last 90 days. Company insiders own 74.00% of the company’s stock.
Institutional Trading of Pulse Biosciences
A number of hedge funds have recently bought and sold shares of PLSE. Osterweis Capital Management Inc. acquired a new position in shares of Pulse Biosciences in the 2nd quarter valued at $28,000. Jupiter Topco LLC bought a new position in shares of Pulse Biosciences during the 2nd quarter worth approximately $241,000. GSA Capital Partners LLP acquired a new stake in Pulse Biosciences in the 2nd quarter valued at $290,000. Cetera Investment Advisers bought a new stake in Pulse Biosciences in the first quarter valued at $387,000. Finally, Legal & General Group Plc acquired a new position in Pulse Biosciences during the second quarter worth $395,000. 76.95% of the stock is owned by institutional investors.
About Pulse Biosciences
Pulse Biosciences, Inc is a medical technology company developing proprietary bioelectric therapies based on its Nano-Pulse Stimulation technology. The platform delivers ultrashort electrical pulses designed to affect targeted cells while limiting thermal damage to surrounding noncellular tissue.
The company’s primary product is the CellFX System, which is designed to deliver Nano-Pulse Stimulation treatments for certain dermatological conditions. Pulse Biosciences is also developing additional applications for its technology in areas including cardiac procedures and other medical specialties.
Pulse Biosciences was founded in 2014 and is headquartered in Hayward, California.
Featured Articles
- Five stocks we like better than Pulse Biosciences
- Chips to Bots: Qualcomm’s Agentic AI Breakout
- Ciena Fell 40%—Now One Analyst Sees 50% Upside
- Energy Transfer Taps the AI Power Boom
- Viking’s Obesity Edge May Be Staying Power, Not Weight Loss
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
